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Introduction : Lors d’insufﬁsance cardiaque (IC), les femmes
presentent une meilleure survie en depit d’une consommation max-x S1.
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about the accuracy of risk assessment by cardiopulmonary exercise
testing (CPET) in women. Accordingly, we aimed to check (1) whether
the predictive role of well-known CPET risk indexes, ie, peak _VO2 and
ventilatory response ( _VE/ _VCO2 slope), is sex independent and (2) if sex-
related characteristics that impact outcome in HF should be consid-
ered as associations that may confound the effect of sex on survival.
Methods: The study population consisted of 2985 patients with HF,
498 (17%) of whom were women, from the multicentre Metabolic
Exercise Test Data Combined with Cardiac and Kidney Indexes
(MECKI): the end point was cardiovascular death within a 3-year
period.
Results: During the follow-up, 305 (12%) men and 39 (8%) women
(P ¼ 0.005) died, and female sex was linked to better survival on
univariate analysis (P ¼ 0.008) and independent of peak _VO2 and _VE/
_VCO2 slope on multivariate analysis. According to propensity score
matching for female sex to exclude a sex selection bias and sample
discrepancy, 498 men were selected: the standardized percentage
bias ranged from 20.8 (P < 0.0001) to 3.3 (P ¼ 0.667). After clinical
proﬁle harmonizing, female sex was predictive of HF at univariate
analysis.
Conclusions: The low peak _VO2 and female association with better
outcome in HF might be counterfeit: the female prognostic advantage
is lost when sex-speciﬁc differences are correctly taken into account
with propensity score matching, suggesting that for an effective and
efﬁcient HF model, adjustment must be made for sex-related
characteristics.
imale d’oxygène ( _VO2) relativement faible : cela jette un doute sur la
precision de l’evaluation des risques au moyen de l’epreuve d’effort
cardiorespiratoire chez les femmes. Par consequent, nous avions
l’objectif de veriﬁer : 1) si le rôle predictif des indices de risque bien
connus de l’epreuve d’effort cardiorespiratoire, c.-à-d. le _VO2 maximal
et la reponse ventilatoire (pente _VE/ _VCO2), dependent du sexe; 2) si les
caracteristiques liees au sexe qui ont des repercussions sur l’evolution
de l’IC devaient être considerees comme des associations pouvant
confondre l’effet du sexe sur la survie.
Methodes : La population à l’etude comptait 2985 patients, dont 498
(17 %) etaient des femmes, souffrant d’IC selon les indices multi-
centriques MECKI (Metabolic Exercise Test Data Combined with Car-
diac and Kidney Indexes) : le critère de jugement etait la mort d’origine
cardiovasculaire au cours d’une periode de 3 ans.
Resultats : Durant le suivi, 305 (12 %) hommes et 39 (8 %) femmes
(P ¼ 0,005) sont morts, et le sexe feminin etait lie à une meilleure
survie à l’analyse univariee (P ¼ 0,008) et independant du _VO2
maximal et de la pente _VE/ _VCO2 à l’analyse multivariee. En fonction de
l’appariement par score de propension selon le sexe feminin pour
exclure le biais de selection lie au sexe et la divergence de
l’echantillon, 498 hommes etaient selectionnes : le biais normalise
exprime en pourcentage variait de 20,8 (P < 0,0001) à 3,3 (P ¼
0,667). Après l’harmonisation du proﬁl clinique, le sexe feminin etait
un predicteur de l’IC à l’analyse univariee.
Conclusions : Le faible _VO2 maximale et l’association du sexe feminin
à une meilleure evolution de l’IC seraient faux : l’avantage pronostique
lie au sexe feminin est perdu lorsque les differences entre les sexes
sont correctement prises en consideration par l’appariement par score
de propension, ce qui suggère que pour un modèle d’IC efﬁcace et
efﬁcient l’ajustement doit tenir compte des caracteristiques liees au
sexe.
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Gender and Cardiopulmonary Exercise TestingThe prognostic value of cardiopulmonary exercise testing
(CPET) in heart failure (HF) has been established in predom-
inantly male cohorts,1 whereas research documents that in
women with HF, a comparatively ﬂawed gas exchange exercise
proﬁle is associated with a better outcome.2-7 This ﬁnding raises
some doubt about the accuracy of risk assessment by CPET in
women with HF,8 even though a low female sample size and
selection criteria might have distorted the result of our study.
The present study was designed to ascertain (1) whether the
predictive role of well-known CPET risk indexes, ie, peak ox-
ygen consumption (peak _VO2) and ventilatory response ( _VE/
_VCO2 slope) is sex independent and (2) if sex-related charac-
teristics that impact outcome in HF should be considered as
associations that may confound the effect of sex on survival.9-11Methods
Study population
The study population was drawn from the database of the
ongoing multicentreMetabolic Exercise Test Data Combined
With Cardiac and Kidney Indexes (MECKI) trial,12 which
consists of consecutive patients with HF caused by systolic
dysfunction who were prospectively recruited and followed.
MECKI exclusion criteria were adopted, plus the following
veto conditions: peak respiratory exchange ratio (RER)
 1.00, exercise limitation other than for fatigue or dyspnea,echocardiographic left ventricular ejection fraction (LVEF)
> 40%, peak _VO2 > 21 mL/kg/min, and CPET performed
on a treadmill.Data collection and management
The Cardiology Centre of Monzino was the coordinating
centre, whereas individual investigators were responsible for
their own records. The following parameters were analyzed at
the time of CPET: patient demographics, cause of HF, resting
cardiac rhythm, New York Heart Association (NYHA) class,
resting LVEF on echocardiography, lifesaving HF therapies,
and blood chemistry data. CPET was performed on an elec-
tronically braked cycle ergometer with a ramp protocol. Peak
_VO2 was measured in the last 30 seconds of the exercise phase,
as was peak RER. The ventilatory anaerobic threshold (VAT)
was measured by V-slope analysis of _VO2 and CO2 production
( _VCO2)
13 and conﬁrmed by ventilatory equivalents and end-
tidal pressures of CO2 and O2. The _VE/ _VCO2 slope (VE is
minute ventilation, in liters/minute, and _VCO2 is CO2 pro-
duction, in liters/minute) was calculated as the slope of the
linear relationship between _VE and _VCO2 from 1 minute after
the beginning of the loaded exercise until the end of the
isocapnic buffering period. The predicted value of peak _VO2
was calculated according to Wasserman et al.14: predicted
peak _VO2 (pp _VO2) ¼ (height  age)*20 if male/*14 if female.
Table 1. Patients’ demographic, clinical, blood chemistry,
ergospirometry characteristics, and follow-up and events rates
according to sex
Variable Men Women P value
Number 2487 498
Age (y) 63  11 61  12 0.006
Body mass index (kg/m2) 27  4 26  5 0.000
NYHA class (I-IV) 2.2  0.6 2.2  0.6 0.485
Atrial ﬁbrillation (%) 423 (17) 58 (12) 0.003
Ischemic cause of heart
failure (%)
1404 (56) 132 (27) 0.000
Left ventricular ejection
fraction (%)
29  7 31  7 0.000
Implanted cardioverter
deﬁbrillator (%)
872 (35) 116 (12) 0.000
ACE inhibitor (%) 1897 (76) 363 (73) 0.121
Angiotensin II receptors
blocker (%)
452 (18) 107 (22) 0.085
b-Blocker (%) 2114 (85) 418 (84) 0.545
Loop diuretic (%) 2125 (85) 408 (82) 0.046
Antialdosterone drugs (%) 1412 (74) 243 (49) 0.001
Digoxin (%) 587 (24) 98 (20) 0.055
Amiodarone (%) 672 (27) 101 (20) 0.002
Nonidentiﬁed VAT (%) 516 (16) 136 (23) 0.000
_VO2 at VAT (mL/kg/min)* 9.7  2.7 9.2  2.6 0.000
Peak _VO2 (mL/kg/min) 13.9  3.4 12.8  3.3 0.000
_VE/ _VCO2 slope 34  7 33  7 0.123
Peak RER 1.13  0.1 1.12  0.1 0.043
Serum creatinine (mg/dL) 1.24  0.4 1.00  0.3 0.000
Serum sodium (mEq/L) 139  3 139  3 0.357
Serum potassium (mEq/L) 4.3  0.4 4.2  0.4 0.000
Hemoglobin (g/dL) 13.7  1.6 12.8  1.2 0.000
Duration of follow-up (d) 846  333 847  334 0.904
Events 305 (12) 39 (8) 0.005
Data are expressed as mean value  standard deviation or number (%) of
patients.
NYHA, New York Heart Association; RER, respiratory exchange ratio;
_VO2, oxygen consumption; _VE, ventilation; _VCO2, CO2 production; VAT,
ventilatory anaerobic threshold.
* _VO2 measured when VAT is detected.
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The study end point was cardiovascular death (CVD), and
the follow-up ended at 1095 days (ie, 3 years) for censored
patients. Events were recorded at the follow-up visits; if a
patient did not show up at the scheduled follow-up visit, the
patient or family was contacted by phone. If a patient died
outside the hospital, medical records of the event and a report
of the cause of death were analyzed, and patients who died of
noncardiovascular-related causes were censored at the time of
the event. Heart transplantation (HT) was not an end point in
order to exclude sex selection and therapeutic bias.15
Statistical analysis
Continuous data were expressed as means  standard de-
viation, whereas categorical data were summarized as counts
and percentages. Characteristics of the sex subgroups (men vs
women) were compared using unpaired Student t tests for
continuous variables and the c2 test for discrete variables.
Statistical signiﬁcance was deﬁned as P < 0.05.
The prognostic inﬂuence of sex was analyzed in the total
study population and in a propensity scoreematched (PSM)
cohort to exclude a sex selection bias and sample discrepancy.16
The female PSM cohort was calculated using logistic regression
analysis with 1:1 matching without replacement. Twenty-one
variables were included in the PSM model: age; body mass in-
dex (BMI); NYHA class; ischemic cause of HF; baseline cardiac
rhythm (presence of atrial ﬁbrillation); LVEF; prescription of
amiodarone, loop diuretic, b-blockers, angiotensin-converting-
enzyme inhibitors, angiotensin II receptor blockers, and digi-
talis; presence of an implantable cardioverter deﬁbrillator
(ICD), peak _VO2; _VE/ _VCO2 slope; VAT identiﬁcation; peak
RER; and serum creatinine, potassium, hemoglobin, and serum
sodium concentrations. Adequacy of propensity score matching
was assessed by standardized percentage bias for full or matched
subsamples.17 Univariate and multivariate Cox regression
models were performed in both the total population and the
PSM cohort; a multivariate analysis model included female sex
and peak _VO2 and _VE/ _VCO2 slope.
All analyses were performed using STATA IC statistical
package, version 11.2 (StataCorp LP, College Station, TX).Results
We screened 3874 patients from theMECKI score database:
3279 (85%) were men and 595 (15%) were women. According
to our study eligibility criteria, 2985 patients with HF were
included in the study, 498 (17%) of whom were women: 792
(24%) men and 97 (16%) women were withdrawn. One
hundred twenty-nine patients (100 men and 29 women were
excluded for LVEF > 40%, 370 patients (351 men and 19
women) for peak _VO2> 21mL/kg/min, 230 patients (201men
and 29 women) for peak RER < 1.05, and 160 patients (140
men and 20 women) for CPET performed on a treadmill.
As Table 1 shows, women with HF were younger and had a
lower BMI, incidence of AF and ischemic cause of HF, and a
higher mean LVEF than did men with HF. Amiodarone, loop
diuretics, and antialdosterone drugs were prescribed less often in
women and ICDs were implanted less often. Although mean
NYHA class was similar, women showed a lower peak _VO2,
percentage of detectable VAT, _VO2 (mL/kg/min) measured atVAT, and peak RER, whereas the _VE/ _VCO2 slope was compa-
rable. Moreover, and as expected, the percentage of pp _VO2 was
higher in women (61%  17% vs 54%  16% for men; P <
0.0001). Finally, lower serum creatinine, potassium, and he-
moglobin values were found in women.
During the 3-year follow-up, 305 (12%) men and 39 (8%)
women (P ¼ 0.005) died. Female sex was linked to a better
survival on univariate analysis, with a hazard ratio (HR) of
0.63  0.10 and a 95% conﬁdence interval (CI) of 0.45-0.88
(P ¼ 0.008). On multivariate analysis, the female sex pro-
tective trait was independent of peak _VO2 and _VE/ _VCO2
slope (Table 2): the model likelihood ratio (LR) c2 was
116.74 (P < 0.001).
According to propensity score matching, 498 men were
selected. Matching was excellent: the standardized percentage
bias was reduced from 20.8% (P < 0.0001) to 3.3% (P ¼
0.667). Covariate variance bias before and after propensity
score matching is shown in Figure 1. In the PSM cohort,
outcome was comparable: 52 (10%) men and 39 (8%)
women died. The female sex outcome beneﬁt was not sig-
niﬁcant on univariate analysis (HR, 0.76  0.15; 95% CI,
0.48-1.11; P ¼ 0.147). When forced, the multivariate analysis
showed that female sex was not prognostically informative,
and only the _VE/ _VCO2 slope was (Table 2) . The LR c
2 of this
model was 26.9 (P < 0.001).
Table 2. CPET variable and gender multivariable analysis model in the
overall population and in the PSM cohort
Variables HR and SD 95% CI P value
Overall population
Peak _VO2 0.83  0.02 0.78-0.89 0.000
VE/ _VCO2 slope 1.05  0.00 1.03-1.06 0.000
Female gender 0.58  0.12 0.78-0.89 0.010
PSM cohort
Peak _VO2 0.93  0.05 0.83-1.05 0.281
_VE/ _VCO2 slope 1.07  0.01 1.03-1.10 0.000
Female gender 0.71  1.78 0.43-1.16 0.175
CI, conﬁdence interval; CPET, cardiopulmonary exercise testing; HR,
hazard ratio; PSM, propensity score-matched; SD, standard deviation; _VE,
ventilation; _VCO2, CO2 production; _VO2, oxygen consumption.
Figure 1. Calibrating plots for sex-related differences, showing varia-
tion of standardized percentage bias for all covariates before and after
the propensity score adjustment. AF, atrial ﬁbrillation; ARB, angio-
tensin II receptors blocker; BMI, body mass index; ICD, implantable
cardioverter deﬁbrillator; IHD, ischemic heart disease; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association; RER,
respiratory exchange ratio; VAT, ventilatory anaerobic threshold; _VE,
ventilation; _VCO2, CO2 production; _VO2, oxygen consumption.
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Gender and Cardiopulmonary Exercise TestingDiscussion
Female patients with HF showed a better prognostic
outcome in this large cohort derived from the MECKI data-
base, even though peak _VO2 was comparatively lower than in
men. Female sex, peak _VO2, and the _VE/ _VCO2 slope had an
independent impact on prognosis in the overall population,
but after propensity score matching harmonization, the
outcome advantage of female sex vanished, whereas the _VE/
_VCO2 slope conserved its predictive capacity. Because
distinctive female factors (eg, biological characteristics) as
recruitment criteria and population compendia (eg, selection
bias) may individually impact outcome in an intertwined
manner, an accurate risk assessment should take into account
the sex proﬁle.12,18-20
Previous experiences are scant,2-7 but they all demonstrate
that peak _VO2 is predictive in women with HF despite dif-
ferences in sample size (generally a low percentage of women
with HF are included in CPET trials), selection criteria
(LVEF and peak _VO2), follow-up duration, and type of events.
Richard et al.2 studied young patients with HF (55 men and
21 women) and found that the event-free survival rate for
CVD and HT was signiﬁcantly higher in women. Elmariah
et al.3 examined 594 outpatients with HF, including 28%
women: 94% of the women vs 81% of the men attained
1-year transplant-free survival, and female survival was supe-
rior in the lower peak _VO2 classes. Guazzi et al.
4 studied 75
women and 337 men with HF: 1-year event rates were
observed in 24% of the female group and 35% of the male
group. Green et al.5 evaluated 278 men and 274 women, and
1-year events were death before HT, implantation of a left
ventricular assist device, or inotrope-dependent trans-
plantation (United Network of Organ Sharing status 1, 1A, or
1B). Event-free survival was similar between women and men,
but women had better survival for a given peak _VO2. Hsich
et al.6 studied 2105 patients with HF, 525 (25%) of whom
were women: during the 5-year follow-up, 129 women (26%)
and 572 men (36%) died (all-cause mortality), but women
were at lower risk of death for any given peak _VO2 value.
Finally, Corrà et al.7 investigated 529 patients with HF (116
women) with peak _VO2  14 mL/kg/min, ie, mean peak _VO2
11.2  1.9 mL/kg/min: 2-year event free survival without
CVD or urgent HT was higher in women (85% vs 66%). As a
ﬁnal point, women live longer even though peak _VO2 is
comparatively lower. Despite this, women showed a distinc-
tive clinical proﬁle, and several sex-speciﬁc features could
impact outcome per se.2-7,21-23 Sex proﬁle mismatching couldbe partially related to inclusion/exclusion criteria and partially
to a conventional way of acting in CPET studies; we believe
that propensity score matching for female sex might close this
gap.
The present study represents the largest CPET population
(second in terms of number of women enrolled) treated with
updated therapy for HF, and the primary end point was
cardiovascular mortality to avoid sex bias regarding HT se-
lection. Clinical and exercise characteristics of female patients
were almost similar to those reported in previous studies,2-7
although better HF treatment (pharmacologic and device
therapy) was witnessed (Table 3). We conﬁrmed that the
percentage of women enrolled is low and that women have
particular features (eg, younger age, higher mean LVEF, lower
mean peak _VO2 at the same peak RER but a higher percent pp
_VO2). Brieﬂy, the “best” clinical and “exercising” women are
usually registered in HF and CPET studies, making most
characteristics not replicable in “general” HF trials.22 Unsur-
prisingly, a low event rate was witnessed: in the general
population, female sex, peak _VO2, and the _VE/ _VCO2 slope
were each independent predictors. Female patients showed a
better survival, even though peak _VO2 was lower than in
men.2-7 Conversely, several sex attributes, over and above
peak _VO2 , in the main study population differed, eg, women
were younger and had lower BMI; incidence of a nonischemic
HF cause, and atrial ﬁbrillation; were treated less often with
antialdosterone drugs; and had higher LVEF. All these fea-
tures might distort and confound the relationship between
survival and peak _VO2 in women with HF, eg, a low peak _VO2
(negative risk factor) could be balanced by a nonischemic
cause of HF in the presence of sinus rhythm (protective ef-
fect). Propensity score matching for female sex was performed
to abate the difference in biological and sex selection. In the
PSM cohort, the female outcome beneﬁt was lost, even
though the percent pp _VO2 difference was still evident by sex
(55%  15% vs 61%  16% in men and women,
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Volume 32 2016respectively), by deﬁnition. Regarding prognosis, sex clinical
proﬁle matching seems to prevail over the persistence of ex-
ercise capacity discrepancy (higher mean percent pp _VO2 in
women): the negligible predictive role of percent pp _VO2 in
the PSM cohort is intriguing and provoking, because it im-
plies that clinical proﬁle harmonizing is essential for outcome
assessment, more so than residual exercise capacity.
Study limitations
First, this study was not designed to evaluate sex risk fac-
tors individually and their predictive ability according to a
hierarchical approach. Second, the prognostic impact of var-
iables was assessed at a single time point; changes, eg, an
upgrading of treatment during follow-up, might have altered
the survival analysis and cannot be excluded. Third, the study
end point was cardiovascular mortality; other causes of death
(ie, sudden cardiac death or worsening of HF) that might be
related to sex were not investigated.24 Fourth, although renal
function, hemoglobin, and electrolyte hemostasis were eval-
uated, other HF-related comorbidities that impact prognosis
were not considered. Finally, we excluded patients with HF
with preserved LV systolic function, a condition more
frequently seen among women.Conclusions
The association of low peak _VO2 and better outcomes in
women with HF might be false if sex-speciﬁc differences are
correctly taken into account. Propensity score matching for
sex in the clinical proﬁle provides a way for truthful risk
assessment, suggesting that for an effective and efﬁcient HF
model, adjustments must be made for sex-related
characteristics.Acknowledgements
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